CDER Officials Testify On Behind-The-Scenes Maneuvers In Plan B Rejection
This article was originally published in The Tan Sheet
The initial rejection of Barr's Rx-to-OTC switch application for Plan B may have been intended to lead eventually to a restricted approval, according to deposition testimony from FDA officials
You may also be interested in...
FDA's decision to approve emergency contraceptive Plan B for over-the-counter sale to women age 18 and older cracks open the door on a pharmacy-only, behind-the-counter model for nonprescription drug sales
The role of high-level FDA officials in the review of Barr Labs' Rx-to-OTC switch application for Plan B was required by the "high-profile" nature of the NDA, according to Center for Drug Evaluation & Research Director Steven Galson
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement